Radiation dermatitis in patients treated with concurrent trastuzumab emtansine (T-DM1).
Clin Transl Radiat Oncol
; 24: 99-101, 2020 Sep.
Article
em En
| MEDLINE
| ID: mdl-32715108
ABSTRACT
Trastuzumab Emtansine (T-DM1) improves outcomes for patients with HER2+ breast cancer, and is given concurrently with radiation. We have noted increased radiation dermatitis in these patients, which may have been underreported on the KATHERINE clinical trial, and call for clinicians to remain vigilant of unexpected toxicities with newly approved therapies.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Idioma:
En
Revista:
Clin Transl Radiat Oncol
Ano de publicação:
2020
Tipo de documento:
Article
País de afiliação:
Estados Unidos